Velphoro did not interfere with the ability
of oral vitamin D to control iPTH1

Velphoro did not interfere with the ability of oral vitamin D to control iPTH1

Velphoro has no meaningful impact on the iPTH-lowering effect of oral vitamin D*1
Velphoro
(n=127)
Sevelamer
carbonate
(n=60)
P=0.012

Velphoro does not interfere with the absorption or activity of
the fat-soluble vitamins A, D, E, and K2,3

Velphoro does not interfere with the absorption or activity of the fat-soluble vitamins A, D, E, and K2,3

  • No additional monitoring required for vitamins A, D, E, and K or folic acid2
Selectivity of Velphoro in patients
taking oral vitamin D

Dr. Shori describes the study findings.

Sandeep K. Shori, DO
Chief of Medicine and Director of Dialysis
Baylor All Saints Medical Center, Fort Worth, Texas
More patients than ever have access

learn more >

More patients than ever have access

learn more >

*Post-hoc analyses to assess for pharmacodynamic interaction of Velphoro with oral vitamin D analogs. Patients taking cinacalcet/cinacalcet hydrochloride to control iPTH were excluded.1

References:
1. Data on file. Fresenius Medical Care North America, Waltham, MA. 2. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America; 2014. 3. Floege J, Covic AC, Ketteler M, et al; on behalf of the PA21 Study Group. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638-647.

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

  • Velphoro must be administered with meals. Velphoro tablets must be chewed and not swallowed whole. To aid with chewing and swallowing, the tablets may be crushed.
  • Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
  • Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. Take doxycycline at least 1 hour before Velphoro. Velphoro should not be prescribed with oral levothyroxine.

For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at
1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.
 

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451